Cancer Immunotherapy Market by Technology (Monoclonal Antibodies, Cytokines & Immunomodulators, and Others), by Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, and Others) by End User (Hospitals,
For more Info and report sample-
The global cancer immunotherapy market is accounted for $45,471 million in 2015, and is estimated to reach $117,114 million by 2022, growing at a CAGR of 14.5% during the analysis period of 2016-2022. Cancer Immunotherapy is a method of cancer treatment that boosts the immune system in fighting cancer. This therapy is more advantageous than the traditional approach as it delivers long-term protection against cancer, has minimal side effects, and avails treatment to more cancer types. Immunotherapy works by guiding system toward cancer-specific targets, followed by activation of immune system to mobilize the target, and produces response that can eradicate cancer targeted cells. There are many factors, such as increase in incidence of cancer, rise in healthcare expenditure, increased access to medical insurance, and technological advancements in cancer treatment therapies that fuel the growth of the global cancer immunotherapy market. However, the factors such as lack of awareness about cancer immunotherapy are anticipated to inhibit the growth of the market. Also, the high product developmental cost is expected to impede the growth of the market.
The market is segmented based on technology, application, end-users, and geography. By technology, this market is categorized into monoclonal antibodies, cytokines & immunomodulators, and other technologies. By application, it is classified into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and other applications. By end-users, it is divided into hospitals, cancer research centers, and clinics. Geographically, it is studied across North America, Europe, Asia Pacific, and LAMEA.
KEY MARKET BENEFITS:
Comprehensive analysis of factors that drive and restrict the growth of the global cancer immunotherapy market is provided.
The projections in the market are made by studying the current market trends and future market potential for the period (2014-2022) in terms of value.
Extensive analysis by technology and application helps understand the various trends and prevailing opportunities in the respective market
Key market players within the global cancer immunotherapy market are profiled in the market and their strategies are analyzed thoroughly, which helps understand the competitive outlook of the global cancer immunotherapy market.
Comprehensive analysis of all regions are provided that determines the prevailing opportunities in these geographies.
For more Info and report sample-
KEY MARKET SEGMENT:
Cytokines & Immunomodulators
Others (Immune Checkpoint Inhibitors, Cell Therapy, and Oncolytic Virus Immunotherapy)
Head & Neck Cancer
Others (Renal Cell Carcinoma, Cervical, Gastric, and Lymphoma)
Cancer Research Centres
List of players profiled in the report
F. Hoffmann-La Roche AG.
Merck & Co., Inc.
Eli Lilly and Company
Bristol-Myers Squibb Company
List of other players (These companies are not profiled in the report and same can be done on demand)
Takeda Pharmaceutical Company Ltd.
For More info.
Raj C (Marketing & Sales)
WESTERN MARKET RESEARCH
Office No.6, CN7, Survey No. 94-95
Pune, Maharashtra, India.
Phone No (US). +1315-359-4245
Phone No (IN) +91 7757044254